Seeett ahddaLeSanniaeeaei, Leeeg a
`
`*y ad:
`PEELOE:
`reacaee
`as
`Wana AU Fa
`Merck 2005
`.4
`Hopewell v Merck
`eleyeoni| Mra inese
`IPR2023-00480
`LEONsirQoDS
`SECONDseen | aaMpa
`
`|
`Sees
`
`oP
`
`7d(AA
`vate:_
`JANET A, HAMILTON, RDR
`
`HkSC
`
`Libraries De
`
`EATETEEDEA AM
`
`sitory
`
`3012215065013
`
`eee apt
`ed eeeee
`
`ROSALIND(erenA
`
`i& eS ha
`“3 fed
`
`wid
`i4
`
`1 i i
`
`

`

`Multiple Sclerosis
`The Questions You Have—
`The Answers You Need
`
`Second Edition
`
`Edited by Rosalind C. Kalb, Ph.D.
`
`

`

`Demos Medical Publishing, Inc., 386 Park Avenue South,
`New York, New York 10016
`
`© 2000 by Demos Medical Publishing, Inc. All rights reserved. This
`book is protected by copyright. No part of it may be reproduced,
`stored in a retrieval system, or transmitted in any form or by any
`means, electronic, mechanical, photocopying, recording, or other-
`wise, without the prior written permission of the publisher.
`
`Library of Congress Cataloging-in-Publication Data
`
`Multiple sclerosis : the questions you have, the answers you need /
`edited by Rosalind C. Kalb.—2nded.
`p.
`cm.
`Includes bibliographical references and index.
`ISBN 1-888799-43-9
`2. Multiple
`1. Multiple sclerosis—Popular works.
`sclerosis—-Miscellanea.
`I. Kalb, Rosalind
`RCG377.M564
`2000
`
`00-035857
`
`616.8’34—dc21
`
`Printed in Canada
`
`Annual updatesto this book can be downloaded from our
`Web site: demosmedpub.com. This site also contains informa-
`
`tion about Demos’s other publications on multiple sclerosis.
`
`

`

`
`
`Foreword
`Acknowledgments
`
`1. What Should I Know About This Book?
`NancyJ. Holland, Ed.D.
`2. Neurology
`Charles R. Smith, M.D., and Randall T. Schapiro, M.D.
`3. Treatment Issues
`Aaron E. Miller, M.D., and Robert M. Herndon, M.D.
`4, Nursing Care to Enhance Wellness
`June Halper, MSN, RN.CS, ANP
`5. Physical Therapy
`Angela Chan, B.P.T., M.H.Sc.
`6. Occupational Therapy
`Jean Hietpas, O.T.R., L.C.S.W.
`7. Speech and Voice Disorders
`Pam Sorensen, M.A., C.C.C.-S.L.P.
`8. Swallowing
`Jeri A. Logemann, Ph.D.
`
`ix
`xi
`
`43
`
`79
`
`105
`
`129
`
`163
`
`177
`
`| This material may be protected by Copyright law (Title 17 U.S. Code)
`—————_—
`
`

`

`CONTENTS
`
`Cognition
`Nicholas G. LaRocca, Ph.D., Pam Sorensen, M.A.,
`CCC-SLP. and Jill Fischer, Ph.D.
`Psychosocial Issues
`Rosalind C. Kalb, Ph.D.,
`and Deborah M. Miller, Ph.D.
`
`Stress and Emotional Issues
`Nicholas G. LaRocca, Ph.D., and Jill Fischer, Ph.D.
`Sexuality
`Frederick W. Foley, Ph.D.,
`and Michael A. Werner, M.D.
`Fertility, Pregnancy, Childbirth,
`and Gynecologic Care
`Kathy Birk, M.D., and Michael A. Werner, M.D.
`Employment
`Phillip D. Rumrill, Jr., Ph.D., CRC
`Insurance Issues
`Robert Enteen, Ph.D.
`
`10.
`
`—11.
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`Long-Term Care
`Debra Frankel, M.S., O.T.R.
`17. Life Planning
`Laura Cooper, Esq.
`Appendixes
`A. Glossary
`—B. Medications Commonly Used in Multiple Sclerosis
`C. National Multiple Sclerosis Society
`Consensus Statement
`
`D. Additional Readings
`
`E.
`
`Resources
`
`Professional Biographies of the Authors
`F.___
`Index
`
`193
`
`221
`
`259
`
`281
`
`311
`
`329
`
`357
`
`387
`
`407
`
`425
`
`453
`
`543
`
`547
`
`555
`
`571
`
`587
`
`

`

`Multiple Sclerosis
`
`The Questions You Have—
`‘The Answers You Need
`
`Edited by ROSALIND C. KALB, Ph.D.
`
`"This book is trustworthy! It is factual! It is honest! It is a jumping-off point to
`learning more about MSand with that knowledge developing new andbetter cop-
`ing skills to deal with the ups and downsof the mysteries of MS."
`.
`From the Foreword by RANDALL T. SCHaAPIRO, M.D.,
`Fairview Multiple Sclerosis Center,Minneapolis
`
`Hereis the definitive guide for anyone concerned with multiple|sclerosis—those
`whohave the. disease, those who share their lives with someone whohasit, arid
`health care professionals involved with its management. Multiple Sclerosis: The
`Questions You Have—The Answers You Need covers a wide range ‘oftopics in a
`question and answer format that,
`is readily accessible and easily understood.'
`Experienced clinicians provide answers to the questions that they have been asked:
`repeatedly. Readers can quickly findinformation about specific topics and ques-
`tions basedon their individual needs.
`
`Each chapter contains a list of references and recommended readings forthose
`interested in pursuing more detailed information ona particular topic. The guide
`also contains a comprehensive glossary of all terms commonly used in MS man-
`agementanda list of relevant resources for individuals with MS and their families.
`The chapter on treatments describes all medications commonly used in the treat-
`ment of MS and the managementofitssymptoms.
`_
`.
`
`i yemos
`DEMOS MEDICAL PUBLISHING
`
`New York, New York 10016
`
`386ParkAvenueSouth,Suite201
`
`ISBN: 1-888799-43-9
`$39.95
`
`Cover DesignDarby Downey
`
`
`
`Il|||
`
`1888°799
`
`
`

`

`Multiple Sclerosis
`The Questions You Have—
`The Answers You Need
`
`Second Edition
`
`Edited by Rosalind C. Kalb, Ph.D.
`
`

`

`Demos Medical Publishing, Inc., 386 Park Avenue South,
`New York, New York 10016
`
`© 2000 by Demos Medical Publishing, Inc. All rights reserved. This
`book is protected by copyright. No part of it may be reproduced,
`stored in a retrieval system, or transmitted in any form or by any
`means, electronic, mechanical, photocopying, recording, or other-
`wise, without the prior written permission of the publisher.
`
`Library of Congress Cataloging-in-Publication Data
`
`Multiple sclerosis : the questions you have, the answers you need/
`edited by Rosalind C. Kalb.—2nd ed.
`.
`em.
`Includes bibliographical references and index.
`ISBN 1-888799-43-9
`2. Multiple
`1. Multiple sclerosis—Popular works.
`sclerosis—-Miscellanea.
`I. Kalb, Rosalind
`RC377.M564
`2000
`616.8'34—dc21
`
`00-035857
`
`Printed in Canada
`
`Annualupdates to this book can be downloaded from our
`Website: demosmedpub.com.This site also contains informa-
`
`tion about Demos’s other publications on multiple sclerosis.
`
`

`

`
`
`This material may be protected by Copyright law (Title 17 U.S. Code)|
`
`Any discussion of treatments for multiple sclerosis must start
`with a careful look at what we mean by the word treatment. To
`most people, being “treated” for an illness means that they
`report their symptomsto a physician, are prescribed a medica-
`tion (an antibiotic, for example}, the symptoms go away, and
`they are cured. In another familiar scenario, the person gets the
`flu or some otherviral infection, goes to the doctor or the phar-
`macy for some medications to relieve discomfort, and waits
`patiently for the virus to run its course and go away. In the case
`of physical injury, the treatment may be even more direct and
`clear-cut. The person who temporarily cannot walk because of a
`broken leg is treated for the injury, and walking ability is
`restored. Of course, the best strategy of all is a vaccine to prevent
`the disease in thefirst place.
`At the present time, none of these familiar notions of treat-
`ment applies in MS. Weare unableto preventtheillness from
`occurring, we do not know howto cureit, we have not found
`a way to restore damaged myelin, axons,or lost functions, and
`the disease is a chronic one that refuses to run its course and
`go away. While efforts continue in the scientific community to
`find a cure for MS and restore damaged myelin, the primary
`
`43
`
`

`

`44
`
`TREATMENTISSUEs
`
`focus of day-to-day medical care in MS is symptom manage.
`ment (see Chapter 2) and efforts to stabilize the disease course,
`These efforts to stabilize the disease are the main focusofthis
`chapter.
`In order to understand why efforts to find an effective treat.
`ment for MS have been so frustrating, it is important to review
`someof the characteristics of the disease. Although webelieve
`MSto be an autoimmunedisease thatis triggered in genetical-
`ly susceptible individuals by some infectious agent in the envi-
`ronment (see Chapter 2), we do not yet have any definitive
`answers. Not knowing the cause of a disease makes lookingfor
`its cure significantly more challenging. Additionally, the disease
`tends to progress quite slowly, with a symptom picturethatis
`highly variable from one person to the next. These characteris-
`tics makeit difficult for researchers to know how toevaluate the
`efficacy of any particular treatment. If the disease manifests
`itself differently from one person to the next, what symptom or
`other aspect of the disease should be looked at to determineif a
`treatment is working?
`Furthermore, although a review of treatments used in MS
`over the 15-year period from 1935 to 1950 indicated that 66
`percent of the patients improved, none of these interventions
`has been shown over time to be any more effective than no
`treatment at all. Other studies have demonstrated that 70 per-
`cent of individuals treated for a recent worseningof their dis-
`ease will improve, at least temporarily, with a placebo, or inac-
`tive, medication. Thus, treatment of a recent exacerbation in
`MScan only be considered effective if it leads to long-lasting
`improvement in significantly more than 70 percent of people
`whoaregivenit.
`This brings us back to the question of measuring the out-
`comes obtained when evaluating experimental
`treatments.
`Recentresearch efforts have targeted the numberof exacerba-
`tions, length of exacerbations, length of time between exacer-
`bations, severity of exacerbations, and the total area or vol-
`ume of lesions shown on MRI as reasonable indicators of
`treatment impact in relapsing-remitting multiple sclerosis. In
`1981, at the first international conference on therapeutic tri-
`als in MS, it was clear that there had been only one success-
`ful treatment trial in MS that met the scientific standards of
`its time.
`In that
`trial of adrenocorticotropic hormone
`
`

`

`MULTIPLE SCLEROSIS: THE QUESTIONS, THE ANSWERS
`
`45
`
`it was demonstrated that ACTH could shorten
`(ACTH),
`attacks even thoughit had no effect on the ultimate degree of
`recovery or long-term disability.
`Since that time, there have been several high-quality drug
`trials in MS. There currently are more trials in progress in
`North America and Europe than at any time in the history of
`the disease. These include small-scale (fewer
`than 20
`patients) and large-scale (several hundred patients)trials, tar-
`geting acute relapses, as well as exacerbating-remitting, sec-
`ondary progressive, and primary progressive MS. They
`involve experimental therapies designed to affect immune
`function, fight infectious agents, restore myelin, and improve
`symptoms. The trials are evaluating new drugs, old drugs,
`and drugs used in various combinations. In addition, treat-
`ments that have already been approved for use in MS are
`beginning to be compared to one another.
`Based on data from recently completed Europeantrials of
`mitoxantrone, an advisory panel for the Food and Drug Admin-
`istration (FDA)
`recommended that
`the FDA approve
`Novantrone® (mitoxantrone for injection concentrate) to slow
`worsening of neurologic disability in secondary progressive and
`relapsing-remitting forms of MS. In recently completedtrials of
`oral myelin, cladribine, and sulfasalazine, these agents were
`found not to be of benefit. Roquinimex (linomide) proved to be
`toxic so thetrial was stopped. As the results from new or ongo-
`ing trials become available, the information will be incorporat-
`ed into periodic updates available from the publisher.
`This is an exciting time for both individuals with MS and
`their health care providers. Interferon beta-1b (Betaseron®),
`the first drug approved by the FDA for treatment of MS,
`became available for relapsing-remitting MS in the fall of
`1993, Betaseron® has had a noticeable impact on the frequen-
`cy and.severity of attacks in many of those receiving the drug.
`In 1994, reports were made of successful trials of interferon
`beta-1a (Avonex® and Rebif®) and glatiramer acetate (Copax-
`one® formerly known as copolymer1) for exacerbating-remit-
`ung MS. Avonex® and Copaxone® are now approved and in
`wide use. In February of 2000, Biogen, Inc. announced the
`early termination of its clinical trial of Avonex® for individu-
`als with initial signs of demyelinating disease whoareat risk
`for developing clinically definite MS. When usedat the stan-
`
`

`

`46
`
`TREATMENTISSugs
`
`dard dose of 30 micrograms in once-weekly intramuscula;
`injections, Avonex® (in comparison to a placebo treatment)
`significantly delayed development of a second objective sign
`that would signal clinically definite MS. [Publication of these
`data, and their review by the FDA had not yet occurred when
`this book went to print.] Rebif® has already been approvedin
`Canada and Europe, and is expected to become available in
`the United States within the next few years. While these offer
`neither a cure nor anyrestoration of lost function, they do rep-
`resent a significant advance in our efforts to stabilize the dis-
`ease process.
`
`What makesit so difficult for scientists to find a cure for multi-
`ple sclerosis?
`
`Physicians and researchers have foundit difficult to find a cure
`for MS because the underlying cause ofthe illness is not known.
`Current thinking is that some “environmental” trigger (a viral
`infection, for example) initiates a process in which the individ-
`ual’s immune system inappropriately attacks the myelin in his
`or her own central nervous system. This process probably
`occurs more readily in people born with a genetic predisposition
`to the disease. Since we do not know the exacttriggers for the
`initial and ongoing immunological assault,
`it
`is difficult to
`devise specific treatments to preventit.
`The ultimate result of the immunologic process in MS is dam-
`age to the myelin and destruction of nerve fibers or axons. While
`myelin has the potential to regenerate to some degree, and does
`so early in the course of the disease, damaged axons do not
`regenerate. Once this damage has proceeded beyondacertain
`point, there are insufficient nerve fibers left to carry out normal
`functions, and permanent weakness, numbness, or visual loss
`begins to occur. Thus, much of the function lost during acute
`attacks early in the disease tends to be recovered, with the
`remaining fibers compensating for those that are lost. As the dis-
`ease progresses, cumulative damage to myelin and nerve fibers
`leads to increasing, persistent neurologic dysfunction. Research
`has also demonstrated that some degree of brain atrophy, or
`shrinkage, occurs in MS, even in the early years of theillness.
`However, the cause or causesof this atrophy remainto be deter-
`mined. At present, we do not know how to repair or restore
`myelin and are,
`therefore, unable to reverse the neurologic
`
`

`

`MULTIPLE SCLEROSIS: THE QUESTIONS, THE ANSWERS
`
`47
`
`symptoms, i.e., cure the disease. One hopeful sign is that we
`have recently come to realize that mammals, including humans,
`do have the capacity for spontaneous repair of central nervous
`em myelin and there is experimental evidence that this
`sta ess can be favorably influenced.
`rocWhen L have an exacerbation my doctor prescribes intravenous
`steroids (e.g., Solu-Medrol®). Why are steroids prescribed and
`what is the difference between steroids taken orally and those
`taken intravenously?
`Steroids are a group of chemicals, some of whichare naturally
`occurring hormones. They have many important hormonal
`functions but they have various additional effects when admin-
`istered as medications (usually in synthetic preparations).
`Their utility in MS stems from their ability to decrease inflam-
`mation in the central nervous system, at least in part by clos-
`ing the damaged blood-brain barrier. Thesteroids used in MS
`should not be confused with the anabolic steroids used by ath-
`letes to build muscle; the corticosteroids used in MS suppress
`inflammation.
`Under normal circumstances, many potentially damaging sub-
`stances are prevented by the blood-brain barrier from passing
`out of the blood stream into the brain and spinal cord. During
`attacks of MS, this barrier can break down andbegin to allow
`damaging chemicals and cells to leak into the central nervous
`system. Inflammation then ensues, resulting in both acute neu-
`rologic injury—sometimes with accompanying symptoms—and
`chronic damage to myelin and axons. Steroids appear to
`decrease this inflammation.
`Most neurologists caring for MS patients believe that steroids
`work best when given directly into the veins in high doses. We
`do not know whether equivalently high doses given orally
`would be equally effective, but some MScenters are takingthis
`approach. In the past, it has been more common to prescribe
`lower doses of steroids orally. However,
`recent studies in
`patients with optic neuritis, a condition that is often the first
`sign of MS,suggest thatthis strategy is less effective than high
`doses given intravenously.
`nesteroids have any long-term benefits? I feel much stronger
`while I’m taking steroids but my doctor says they should not be
`used frequently or for very long periods. Whynot?
`
`

`

`48
`
`TREATMENT ISSUES
`
`Continuous administration of steroids has never been shownto
`provide long-term benefits for people with MS. Thereis some
`suggestion that short courses of high-dose intravenoussteroids
`may have a longer-term benefit in delaying further disease actiy.
`ity. Many people feel better while taking steroids,
`in pant
`because these drugs can have a mood-elevating effect. However,
`the chronic use of steroids is fraught with many potentially dan-
`gerous side effects and is currently thought to be unwisein the
`treatment of MS. Their long-term use can be associated with
`such side effects as hypertension, diabetes, bone loss (osteo-
`porosis), cataracts, and ulcers. These potential detrimental
`effects outweigh the possible benefits whensteroidsare used on
`an extended basis.
`
`WhenI take steroids I get very emotional and have intense
`mood swings.I also feel very down or depressed toward the end
`of the treatment. Why does this happen andis there anythingto
`do aboutit?
`
`Short courses of steroids, even in very high doses, are usually
`well-tolerated. Many people, however, do have some minor
`mood changes, both highs and lows. Others may have difficulty
`sleeping. A much smaller group of individuals may have more
`severe disturbances in mood or behavior. Lithium, a medication
`often prescribed for people with bipolar disorder (formerly
`called manic-depressive disorder), is sometimes used to prevent
`or manage these mood swings. Carbamazepine (Tegretol®) and
`divalproex (Depakote®) have also been shownto beveryeffec-
`tive. On occasion, antidepressant medications may be pre-
`scribed, but they are seldom needed becausethe “blues” associ-
`ated with a short course of steroids usually disappear sponta-
`neously before the antidepressants would begin to take effect
`(usually a few weeks).
`
`Once a promising new treatment has been identified, why does
`it take such a long timefor it to be available for patients?
`Unfortunately, the process of new drug developmentis very
`slow, particularly for a chronic disease like MS. The typical
`sequenceinitially begins with animal studies (see Fig. 3-1). This
`is a crucial first step because an experimental model for MS,
`experimentalallergic encephalomyelitis (EAE), exists in labo-
`ratory rodents (as well as other species). This allows a quick
`
`

`

`MULTIPLE SCLEROSIS: THE QUESTIONS, THE ANSWERS
`
`49
`
`Summary table of steps involved in the developmentof a
`
`Figure 3-1.
`new drug
`Oe
`© Preclinical Phase
`Animal studies
`© Phase |
`Preliminary humanclinical trials
`<p» small, unblinded, open labeltrials (for safety)
`¢4 small, often double-blind, for additional safety
`and efficacy information
`Multicenter, randomized, double-blind, placebo-
`controlled trials needed for FDA approval
`
`© PhaseIl
`
`© PhaseIll
`
`© Data Analysis
`© Application for approval of drug by the FDA
`© Pharmaceutical company brings drug to market
`
`assessmentof the possible benefits of a treatment, as well as the
`preliminary evaluation of its safety. A promising agent then
`moves into human clinicaltrials.
`Human clinical
`trials begin with very small “open label”
`(unblinded) trials in which the physicians and subjects know
`what drug is being taken. Initially, these are usually donein nor-
`mal individuals without known disease. An unblinded trial is
`aimed at demonstrating the safety of a treatment and maybefol-
`lowed by an opentrial in a few patients with known disease.
`These trials are typically of much shorter duration than later
`studies, but still take many monthsto a year or longer because of
`the variable nature of MS. The open labeltrials are then fol-
`lowed by relatively small, usually double-blind, pilot
`trials
`designed to give stronger evidence suggesting that a newtreat-
`ment may be effective as well as safe. “Double-blind” means that
`neither the subject nor the investigators know which subjects are
`receiving the real medication and whichare getting the placebo
`(an inactive substance). This procedure is followed in order to
`prevent hopes and expectations on the part of researchers or
`subjects from affecting the course or evaluation of the treatment.
`If the drug still appears promising, testing will move into
`Phase III, involving large, multicenter, randomized, placebo-
`controlled, double-blind trials. In this stage of drug develop-
`ment, typically hundreds of subjects are entered into a study in
`which some are randomly assigned to receive the medication
`and others to get placebo. Because MSis a chronic disease in
`which changes occur relatively slowly in most people, these
`
`

`

`50
`
`TREATMENT ISSUES
`
`PhaseIII trials typically last for several years in order to obtain
`enough information on which to base fair and statistically valiq
`conclusions. Thesetrials are expensive, costing many millions
`of dollars that are essentially wasted if the drug does not work.
`This accounts, in large part, for the high cost of new drugs.
`Following the completionof thetrial, another six months may
`be necessary to analyze the large quantity of data and prepare
`submission of documents to the Food and Drug Administration
`(FDA). The FDA, which is ultimately responsible for the
`approval of new drugs, carefully reviews both the data and the
`methodology of the trial. This agency must be convincedof both
`the effectiveness and safety of the treatment before giving its
`approval. The review process typically takes another six to
`twelve months. Finally, after approval of a drug, the pharmaceu-
`tical company typically needs a few more monthsto get the drug
`to market.
`Thus, the process is extremely long and arduous, as well as
`very frustrating for people with MS andtheir families. However,
`it is a process designed to assure that everyone receivessafe
`treatments and that no one misses out on the opportunity to take
`other, potentially useful treatments while taking something that
`is ineffective. The problem with manyof the publicly acclaimed
`“treatments” that receive so much attention in the press (e.g.,
`snake venom and the removal of tooth amalgams) is that they
`have not been through this process. In other words, they have
`not been provento be safe or effective in a clinical trial and can
`sometimes be quite harmful.
`Whatis the “placebo effect?”
`A placebois a non-active substance that is designed to look just
`like the drug that is being evaluated in a research protocol.
`Investigators repeatedly find that a substantial proportion of
`patients with a variety of diseases experience some benefit even
`when they are treated with a placebo. This phenomenonis
`knownas the placeboeffect. Although this effect may occur in
`part
`through unconscious psychological mechanisms,
`some
`studies have also demonstrated the production of certain chem-
`icals in such individuals that may contribute to this improve-
`ment. Even though the benefits are not usually sustained, this
`short-lived effect confounds the study of new drugs. Random-
`ized, placebo-controlled, double-blind trials are used in order to
`
`

`

`MULTIPLE SCLEROSIS: THE QUESTIONS, THE ANSWERS
`
`351
`
`determine the advantage (if any) that the new drug shows over
`placebo effects. Thus, to demonstrate the value of a newtreat-
`ment, it must be proven to have a benefit superior to that offered
`by a placebo.
`|
`|
`It is important to rememberthat being treated with a placebo
`is not the same as receiving no treatment. Taking the placebo fos-
`ters certain expectations for improvementthat are not present
`when no treatment is given. That is why new drugs are always
`compared with a placebo rather than with no treatmentatall.
`The drug must demonstrate a specific benefit beyond the place-
`bo effect or the improvement that might occur spontaneously
`with no treatment, or with an existing treatment. Now, with the
`availability of several treatments for relapsing-remitting MS,
`many future trials will probably compare a new drug with an
`existing drug rather than with placebo.
`If alternative treatments like bee stings and cobra venom work
`well for some people, why aren’t they more widely prescribed?
`
`Alternative treatments for MS such as beestings are often tout-
`ed as helping people with MS. The problemis that these reports
`are always “anecdotal”; they consist mostly of individual claims
`of success, without any scientific study. It is well-known that
`MS often undergoes spontaneous improvement or remission.
`Furthermore, as discussed previously, virtually every study of
`MSindicates a significant placebo effect, whereby people taking
`placebo (non-active substance) do better than they would with
`no treatment. Therefore, claims of success with any therapy,
`including alternative treatments, must be regarded with consid-
`erable skepticism unless controlled clinical
`trials are done.
`Additionally, some of these treatments, such as bee stings, carry
`potentially severe risks. Specifically, fatal allergic reactions can
`occur in some individuals receiving bee stings. These comments
`are not to suggest that there might not be merit to somealterna-
`tive treatments, but rather to emphasize the importance of prop-
`er scientific investigation under controlled and safe conditions.
`Who designs clinical trials and decides when and where they
`will take place, and who can participate?
`ine trials may originate from several different sources. Early
`h 8 are often initiated by investigators interested in MS,
`whereas more definitivetrials of promising new treatments are
`
`

`

`52
`
`TREATMENTISSUES
`
`generally undertaken by pharmaceutical companiesinteresteq
`in marketing a product. Although these companies often haye
`physicians and basic scientists in their direct employment, they
`usually recruit outside investigators to help plan a clinical triaj
`Then, depending onthesize of the study, additional investiga.
`tors are invited to participate in the trial in order to enter the
`required number of subjects as quickly as possible. The lead
`investigators design the protocol or formatfor the trial, deciding
`how thetrial will be carried out and whowill beeligible to par-
`ticipate. The design of the trial is then submitted to the Food and
`Drug Administration for approval before thetrial is begun.
`Howcan I getinto a clinicaltrial?
`Various sources of information about clinical trials are available.
`The best place to start is with your own physician, who will often
`be able to direct you to a particular trial. The National Multiple
`Sclerosis Society can also provide information aboutthesites par-
`ticipating in particular clinical trials. Some of the local chaptersof
`the National Multiple Sclerosis Society publish newsletters in
`which they announcetrials in their area. Many of the member
`centers of the Consortium of Multiple Sclerosis Centers (see
`Appendix E, Resources) participate in one or moreclinicaltrials.
`It is important to rememberthat eachtrial has a very specific pro-
`tocol that details the types of patients who areeligible to partici-
`pate. For sometrials, the eligibility criteria are quite restrictive; for
`others, the criteria are more liberal. Your willingnessto participate
`in a Clinical trial is greatly appreciated by investigators because
`successful completion of such studies is the only way that wewill
`definitively identify effective new treatments. Do not be discour-
`aged if you do not meetthe entrancecriteria for a particular trial.
`Keep informed—thenext one mightberight for you.
`WhyshouldI participatein a clinicaltrial if I have a significant
`chanceofgetting the placebo instead of the real drug?
`There are several reasonsto participate in clinical trials.
`
`© It has been demonstrated repeatedly in MStrials that even
`those subjects who receive the placebo usually do better
`than they would have done without any intervention. The
`quality of medical care in trials tends to be very high, and
`is provided without cost to the participants.
`
`

`

`MULTIPLE SCLEROSIS: THE QUESTIONS, THE ANSWERS
`
`53
`
`© Clinical trials are the best mechanism currently available to
`identify effective treatments; therefore, your participation
`ultimately helps investigators answer important questions.
`© Standard, accepted treatments continue to be allowed
`under the research protocols of most placebo-controlled
`trials. For example, acute exacerbations could be treated
`with steroids in the interferon beta-1b (Betaseron®) and
`interferon beta-1a (Avonex®)trials.
`© With Betaseron®. Avonex®. and Copaxone® currently
`available in the United States, Rebif® available in Cana-
`da and Europe, and Novantrone® recommended for
`approval by the FDA,it is likely that we will shift away
`from placebo-controlled trials to drug comparisontrials
`in which a proposed new drug will be compared with the
`most effective available drug. Thus, any proposed new
`drug would have to demonstrate its superiority over
`those that have already been approved for use. Partici-
`pants in this type of drug comparison trial would there-
`fore be randomly assigned to either the proposed drug or
`one that has already been shownto be effective in treat-
`ing MS.
`
`Why do so manyclinical trials require that participants be able
`to walk?
`
`The entrance criteria for particular trials are very specific. Many
`of the trials require that subjects be able to walk, sometimes
`without the use of aids. This requirement is made becauseitis
`often more difficult to detect changes in disease activity in indi-
`viduals whose illness is more advanced, and the inclusion of
`people with more advanced disease might cause investigators to
`discard potentially useful treatments because they erroneously
`failed to detect a benefit.
`
`Why were the disease-modifying agents (Betaseron®, Avonex®,
`Copaxone®, and Rebif® [not available in U.S.]) originally tested
`on people with relapsing-remitting disease?
`These agents (see Appendix B) were originally tested on people
`with telapsing-remitting MS because investigators thought those
`with milder disease would be more likely to show a benefit from
`teatment. Also, previous studies had shownthatit might be
`
`€
`

`

`54
`
`TREATMENTISSUggs
`
`easier to demonstrate an effect by measuring a reduction in
`attack rate than by showing a reduction in disease progression,
`How does Copaxone® differ from the interferon medications,
`Betaseron®, Avonex®, and Rebif® [not available in U.S]?
`Betaseron®, Avonex®, and Rebif® are interferons, a group of
`immunesystem proteins, produced andreleased bycells infect-
`ed by a virus, which inhibit viral multiplication and modify the
`body’s immune response. Copaxone® is unrelated to the inter-
`ferons. It is a synthetic polypeptide (like a protein) that mayact
`by fooling the immunesystem, and by suppressing the immune
`attack on myelin that is believed to occur in MS.
`Copaxone® is administered by daily subcutaneous(underthe
`skin) injection. Unlike Betaseron®, Avonex®, and Rebif®, it does
`not cause flu-like reactions. Injection-site reactions are general-
`ly minor. Depression, which has been associated with all inter-
`ferons administered in high doses for human disease, does not
`occur with Copaxone®. However, people whoare taking Copax-
`one® should be aware of one peculiar reaction that, although
`infrequent, can be quite alarming. On rare occasions {perhaps
`once in 800 to 1,000 injections), a person taking Copaxone® may
`experience an immediate post-injection reaction involving sen-
`sations of tightness in the chest and flushing of the face, perhaps
`accompanied by palpitations, shortness of breath, or anxiety.
`This reaction passes within 15 to 30 minutes and has never
`proved to be serious.
`Table 3-1 compares the four drugs currently approvedforthe
`treatment of relapsing-remitting MS. Note: Betaseron®, Avonex®,
`and Copaxone® have been approved in the United States and
`Canada. Betaseron® is approved in Canada and Europefor both
`relapsing-remitting and secondary-progressive MS. To date,
`Rebif® has been approved only in Canada and Europe.
`At a recent MS educational meeting, sponsored by my local
`chapter of the National Multiple Sclerosis Society, I heard
`about a drug named Rebif®. Whatis it, and why isn’tit avail-
`able in the United States?
`Rebif®, like Avonex®, is beta interferon-1a. In a multicentertrial
`in Canada, Europe